Novel treatments for chronic hepatitis C: closing the remaining gaps


    loading  Checking for direct PDF access through Ovid

Abstract

HIGHLIGHTSDespite the great success of DAAs, certain patients will benefit from newly approved regimens.SOF/VEL/VOX showed 96% cure rate in patients that failed prior DAAs.G/P is an approved 8-week regimen for treatment-naive, non-cirrhotic patients regardless of genotype.G/P can be used in patients with advanced kidney disease.Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >90% for the majority of patients and excellent safety profile. However, there remain certain unmet needs in treating HCV including treatment for patients that failed a prior DAA regimen and for those with advanced chronic kidney disease. In addition, shortening the duration of DAA regimens has the potential to increase compliance and decrease the cost of care. New regimens that were approved by the FDA in 2017 address these unmet needs and will be discussed in this concise review.

    loading  Loading Related Articles